Stockreport

FDA Grants Fast Track Designation to Kymera Therapeutics, Inc. (KYMR)'s KT-621 for Eosinophilic Asthma [Yahoo! Finance]

Kymera Therapeutics, Inc.  (KYMR) 
PDF TheFly reported on April 13 that KYMR announced that the U.S. Food and Drug Administration granted Fast Track designation to KT-621, its first-in-class oral STAT6 degra [Read more]